Beijing Chunlizhengda Medical Instruments (01858) announced its performance forecast for 2025, expecting a net profit attributable to shareholders of between 2.45 billion and 2.88 billion yuan, a year-on-year increase of 96.01% to 130.41%.

Beijing Chunlizhengda Medical Instruments (01858) released its performance forecast for 2025. According to the preliminary calculations of the company's financial department, it is expected that the net profit attributable to the owners of the parent company in 2025 will be between RMB 2.45 billion and RMB 2.88 billion, an increase of RMB 1.2 billion to RMB 1.63 billion compared to the same period last year, representing a year-on-year increase of 96.01% to 130.41%. The net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be between RMB 2.3 billion and RMB 2.7 billion in 2025, an increase of RMB 1.35 billion to RMB 1.75 billion compared to the same period last year, representing a year-on-year increase of 142.80% to 185.11%. The announcement stated that in 2025, the net profit attributable to shareholders and the net profit excluding non-recurring gains and losses both achieved significant growth compared to the previous year. During the reporting period, the company's product lines gradually unleashed growth potential after being included in centralized procurement. At the same time, the company continues to implement its international development strategy and steadily promote the international business layout, both internally and externally, to drive sustainable and healthy growth of operating income. Additionally, the company focuses on improving operational management levels, optimizing resource allocation, and further enhancing operational efficiency to strengthen overall profitability, providing solid support for performance growth.